News
-
-
PRESS RELEASE
Inside Information / Operations of the issuer (acquisitions, sales...)
Median Technologies receives FDA 510(k) clearance for eyonis® LCS, the first AI tech-based detection and diagnosis device for lung cancer screening. The device aims to redefine lung cancer screening with high accuracy and potential to save lives -
-
-
PRESS RELEASE
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Median Technologies discloses total voting rights & shares as of Nov 30, 2025, in compliance with French regulations. Company pioneers AI for cancer diagnosis & treatment -
-
-
-
PRESS RELEASE
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Median Technologies discloses total voting rights and shares as of July 31, 2025, per French regulations. The company pioneers AI-driven medical software for cancer diagnosis and treatment -
